<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847349</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2021000186</org_study_id>
    <nct_id>NCT04847349</nct_id>
  </id_info>
  <brief_title>Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial</brief_title>
  <official_title>Live Microbials to Boost Anti-SARS-CoV-2 Immunity Clinical Trial (Live BASIC Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vault Health, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot double-blind randomized controlled trial will test the preliminary efficacy of two&#xD;
      doses of a combination of live microbials (probiotics) given to boost the immunity of&#xD;
      unvaccinated persons previously infected with SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot double-blind randomized controlled trial will test the preliminary efficacy of two&#xD;
      doses (a standard dose and a high dose) of a combination of live microbials (probiotics),&#xD;
      currently marketed in food (including products labeled as dietary supplements), given daily&#xD;
      for 21 days to boost the immunity of unvaccinated, generally healthy persons ages 18-60 with&#xD;
      prior confirmed SARS-CoV-2 infection. Data collected will include demographics,&#xD;
      comorbidities, medications, information about prior SARS-CoV-2 infection, and self-reported&#xD;
      symptoms and adverse events (AEs). Biospecimens (saliva, nasal wash, blood, and stool) will&#xD;
      be collected at baseline and days 21 and 42 for analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in titer of serum anti-SARS-CoV-2 immunoglobulin G (IgG)</measure>
    <time_frame>between baseline and day 21 (day 1 is the first day of taking the investigational product)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the titer of serum anti-SARS-CoV-2 IgG</measure>
    <time_frame>between baseline and day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the titer of serum anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>between baseline and days 21 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the titer of serum and nasal anti-SARS-CoV-2 immunoglobulin A (IgA) antibody</measure>
    <time_frame>between baseline and days 21 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-vitro changes in cytokine release in response to stimulation of peripheral blood mononuclear cells with SARS-CoV-2 peptides</measure>
    <time_frame>between baseline and days 21 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokine levels</measure>
    <time_frame>between baseline and days 21 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in any baseline symptoms from prior SARS-CoV-2 infection</measure>
    <time_frame>up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New (repeat) SARS-CoV-2 infections</measure>
    <time_frame>up to 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Live microbial (Probiotic) consortium OL-1, standard dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of a standard dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Live microbial (Probiotic) consortium OL-1, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of a high dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for live microbial (probiotic) consortium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics, taken once per day with breakfast for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OL-1, standard dose</intervention_name>
    <description>The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.</description>
    <arm_group_label>Live microbial (Probiotic) consortium OL-1, standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OL-1, high dose</intervention_name>
    <description>The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.</description>
    <arm_group_label>Live microbial (Probiotic) consortium OL-1, high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.</description>
    <arm_group_label>Placebo for live microbial (probiotic) consortium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults (any gender, ages 18 to 60 years old) in good general health, based on&#xD;
             medical history&#xD;
&#xD;
          -  SARS-CoV-2 infection &gt;4 months prior confirmed by a positive polymerase chain reaction&#xD;
             (PCR) or antigen test&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5-39.9 kg/m2&#xD;
&#xD;
          -  Agreement to comply with the protocol and study restrictions&#xD;
&#xD;
          -  Access to internet in addition to willingness and ability to use web-based&#xD;
             questionnaires&#xD;
&#xD;
          -  Available for all study visits&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent infection with coronavirus disease-2019 (COVID-19) (newly positive PCR or&#xD;
             antigen test within prior 4 months)&#xD;
&#xD;
          -  Prior receipt of antibody therapies (convalescent or monoclonal) towards COVID-19&#xD;
&#xD;
          -  Prior receipt of vaccines against COVID-19&#xD;
&#xD;
          -  Prior or current participation in a clinical trial of vaccines against COVID-19&#xD;
&#xD;
          -  Scheduled to receive a vaccine against COVID-19 in the following month&#xD;
&#xD;
          -  Regular use of any live microbial (probiotic) supplements&#xD;
&#xD;
          -  Any acute or chronic respiratory tract disease besides mild to moderate asthma&#xD;
&#xD;
          -  Any diagnosed immunodeficiency&#xD;
&#xD;
          -  Current use of immunosuppressive drugs&#xD;
&#xD;
          -  Any diagnosis of chronic gut disease, such as inflammatory bowel disease or irritable&#xD;
             bowel syndrome&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Recent use of antibiotics&#xD;
&#xD;
          -  Current addiction to alcohol, drugs, or medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel B Horton, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vault Health, Inc.</last_name>
    <phone>929-390-4709</phone>
    <email>clinical_trials_support@vaulthealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rutgers University</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vault Health, Inc.</last_name>
      <phone>929-390-4709</phone>
      <email>clinical_trials_support@vaulthealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://learn.vaulthealth.com/rutgers-trial/</url>
    <description>Trial landing page with screening form to confirm eligibility</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 18, 2021</last_update_submitted>
  <last_update_submitted_qc>April 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Daniel B. Horton, MD, MSCE</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics and Epidemiology</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Saliva, nasal rinse, blood samples, and stool samples collected will be used for the purposes of this research.&#xD;
After information that could identify consenting participants has been removed, de-identified information and left over biospecimens collected for this research may be used by or distributed to the study funder (Danisco USA Inc.) or to investigators for other research without obtaining additional informed consent. Personal identifying details, such as name and date of birth, will not be shared without participants' additional permission.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be shared after enrollment and data analysis are completed.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

